Related Experiment Videos
Esomeprazole: a proton pump inhibitor.
Ravi Vachhani1, Gregory Olds, Vic Velanovich
1Virginia Commonwealth University, PO Box 980341, Richmond, VA 23298, USA. rvachhani@mcvh-vcu.edu
Expert Review of Gastroenterology & Hepatology
|February 13, 2009
Summary
Proton pump inhibitors (PPIs) are effective for acid-related disorders. Esomeprazole, a newer PPI, shows variable clinical benefits compared to others, with cost influencing prescribing patterns.
Area of Science:
- Pharmacology and Gastroenterology
- Drug efficacy and comparative analysis
Background:
- Proton pump inhibitors (PPIs) are the most potent gastric acid secretion inhibitors.
- They are widely used for various acid-related gastrointestinal disorders.
- Esomeprazole, a newer PPI, entered the market in 2001.
Purpose of the Study:
- To review the indications and comparative efficacy of esomeprazole.
- To assess the clinical importance of reported differences between esomeprazole and other PPIs.
- To understand the role of cost in PPI prescribing patterns.
Main Methods:
- Literature review of studies comparing esomeprazole with other PPIs.
- Analysis of clinical trial data regarding efficacy and safety.
- Consideration of economic factors influencing therapeutic choices.
Main Results:
- Esomeprazole is indicated for gastroesophageal reflux disease, NSAID-associated ulcers, H. pylori eradication, and Zollinger-Ellison syndrome.
- Studies report some differences favoring esomeprazole over other PPIs.
- The magnitude of these differences is variable and of uncertain clinical significance.
Conclusions:
- Esomeprazole is a versatile PPI with established indications.
- While some comparative advantages exist, their clinical impact is not definitively established.
- Cost is a significant determinant in the selection of PPIs for clinical practice.
Related Concept Videos
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
01:26Peptic Ulcer Disease IV: Management
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
01:31Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
However, this neutralization reaction between...